Samsung Biologics is a fully integrated CDMO offering state-of-the-art contract development and manufacturing services. With proven regulatory approvals, the largest capacity, and the fastest throughput, Samsung Biologics is an award-winning partner of choice and is uniquely able to support the development and manufacturing of biologics products at every stage of the process while meeting the evolving needs of biopharmaceutical companies worldwide.
我们正在追踪 Samsung Biologics 的市场扩张
最近 90 天内有 8 个信号。
Samsung Biologics 的国际扩张与竞争对手的对比情况
Samsung Biologics你条形图显示所对比公司之间的相对规模。
列5| 公司 | 市场 | 新市场 | 势头 | 活动 | 扩张评分 |
|---|---|---|---|---|---|
 Samsung Biologics你 | 0 | 0 | — | 0 | 0 |
当前没有招聘
注册以跟踪该公司，并在发生变化时第一时间获得提醒。
The delivery of safe, high-quality medicines demands a culture where precision and compliance are deeply ingrained at every level. Dr Diane Black, EVP and Chief Quality Officer at Samsung Biologics, shares how our quality approach is put into practice through continuous process improvement. Our quality teams maintain a consistent presence on the manufacturing floor, providing real-time oversight and hands-on support throughout production. This close alignment strengthens process control, keeps p ...
已结束受中东紧张局势影响,韩国综合指数收于6475.63点近乎持平,而科斯达克指数飙升2.51%至1203.84点,自2000年以来首次突破1200点。
韩国综合股价指数上涨2.25%至8228.70点,受半导体股推动,SK海力士飙升9.31%,三星电子上涨2.68%,而KOSDAQ下跌3.36%,市场呈现两极分化。
解锁已验证邮箱与直拨电话
免费 · 无需信用卡
关于 Samsung Biologics 的业务、市场和增长信号的快速解答。
